Hinge Health, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $HNGE in the last 7 days.
Budge James (Chief Financial Officer) sold 47,720 shares of Hinge Health, Inc. (HNGE) at an average of $103.13 ($101.53–$104.34, $4.92M total) across 4 trades on 2026-10-12 under a Rule 10b5-1 trading plan.
Mecklenburg Gabriel M.I. sold 200,000 shares of Hinge Health, Inc. (HNGE) at an average of $103.13 ($101.53–$104.34, $20.63M total) across 4 trades on 2026-10-12 under a Rule 10b5-1 trading plan.
Biotech stocks BIIB, RTSN, CON, HNGE, and HSTM reached 52-week highs on October 12, 2026. BIIB hit $230.49 after positive clinical data for Litifilimab. RTSN rose 7% to $11.32 post-IPO. CON reported Q2 revenue growth of 10% to $606M. HNGE saw Q2 revenue rise 53% to $212M and acquired Cylinder Health. HSTM's Q2 revenue grew 12.5% to $83.7M.
Recent HNGE coverage spans insider activity, financial news and market movers.
In the last 30 days, HNGE insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($26.0M). The most active reporter was Budge James, Chief Financial Officer, with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may signal confidence concerns, likely putting downward pressure on the stock.
Insider selling at this size can pressure sentiment, but it is not inherently bearish given the stated 10b5-1 plan and the director role.
Robust growth and acquisition news may drive further price gains.
The statement may generate speculative buying pressure as investors anticipate deal announcements.
The announcement sets the date for the upcoming earnings release, providing a known catalyst but no new financial data.
AlphAI scores every news story that mentions HNGE with an AI model for sentiment and relevance, and aggregates insider trades from Hinge Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Budge James (Chief Financial Officer) sold 47,720 shares of Hinge Health, Inc. (HNGE) at an average of $103.13 ($101.53–$104.34, $4.92M total) across 4 trades on 2026-10-12 under a Rule 10b5-1 trading plan.
1 min readMecklenburg Gabriel M.I. sold 200,000 shares of Hinge Health, Inc. (HNGE) at an average of $103.13 ($101.53–$104.34, $20.63M total) across 4 trades on 2026-10-12 under a Rule 10b5-1 trading plan.
2 min readBiotech stocks BIIB, RTSN, CON, HNGE, and HSTM reached 52-week highs on October 12, 2026. BIIB hit $230.49 after positive clinical data for Litifilimab. RTSN rose 7% to $11.32 post-IPO. CON reported Q2 revenue growth of 10% to $606M. HNGE saw Q2 revenue rise 53% to $212M and acquired Cylinder Health. HSTM's Q2 revenue grew 12.5% to $83.7M.
2 min readHinge Health (HNGE) plans to pursue more acquisitions, particularly in hardware, to drive growth, according to CEO Daniel Perez. The company aims to complement its virtual care offerings with strategic deals, reports Bloomberg.
1 min readHinge Health, Inc. (HNGE) announced it will release Q3 2026 earnings after market close on Nov. 2, 2026, followed by a conference call at 4:30 p.m. ET. The details will be available on the company's investor relations website.
1 min readCareDx (CDNA), AVITA Medical (RCEL), Azenta (AZTA), and Hinge Health (HNGE) reached 52-week highs on October 2, 2026. CDNA reported $132M Q2 revenue, up 52% YoY. RCEL saw 18% Q2 revenue growth. AZTA reported 12% Q3 revenue growth. HNGE saw 53% Q2 revenue growth and acquired Cylinder Health for $105M.
2 min readOn September 30, 2026, biotech stocks PGEN, EXEL, TWST, HNGE, and PBYI hit 52-week highs. PGEN rose 6% to $9.98, EXEL reached $61.14, TWST climbed 3% to $197.19, HNGE hit $98.41, and PBYI touched $10.10. Key catalysts included clinical trial results, FDA designations, and revenue growth.
2 min readAnalysts updated price targets for several companies. Piper Sandler raised Microsoft's target to $610, maintaining an Overweight rating. Other notable changes include Carmax, Accelerant, Jack Henry, Moderna, Grocery Outlet, Hinge Health, Aytu Biopharma, NetApp, and Ferrari.
2 min readPursley James (President) sold 33,000 shares of Hinge Health, Inc. (HNGE) at an average of $94.14 ($93.37–$95.10, $3.11M total) across 3 trades on 2026-09-21 under a Rule 10b5-1 trading plan.
1 min readOsterweis Opportunity Fund reported a 35.34% Q2 2026 return, outperforming the Russell 2000 Growth Index. Hinge Health (HNGE) was a top performer, with shares up 4.03% in the past month and 73.61% over the year. The company reported 52% year-over-year Q2 billing growth and raised guidance, but the fund noted growth may not be sustainable.
1 min read
